PRFXPAINREFORM LTD.

Nasdaq painreform.com


$ 0.81 $ -0.10 (-10.7 %)    

Tuesday, 17-Sep-2024 15:54:44 EDT
QQQ $ 473.83 $ -2.14 (-0.45 %)
DIA $ 417.12 $ -0.26 (-0.06 %)
SPY $ 563.14 $ 0.30 (0.05 %)
TLT $ 100.82 $ -0.51 (-0.5 %)
GLD $ 237.35 $ -1.31 (-0.55 %)
$ 0.9071
$ 0.88
$ 0.81 x 100
-- x --
$ 0.81 - $ 0.88
$ 0.76 - $ 23.88
548,806
na
261,297
$ 0.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 painreform-shares-are-trading-lower-today-whats-going-on

PainReform Ltd. (NASDAQ: PRFX) experienced a decline Tuesday following the company's announcement of a warrant exercise. Th...

 painreform-13d-filing-shows-lia-pure-capital-ltd-1-reported-a-720-stake-in-the-co-as-of-august-22-2024

- SEC Filing

 painreform-confirms-optimal-delivery-method-for-prf-110-in-bunionectomy-procedures-study

PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110's Competitive Edge Over ...

 painreform-announces-development-and-manufacturing-of-new-formulations-providing-anti-inflammatory-and-extended-analgesic-effects

PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical compan...

 painreform-announces-prf-110-promoted-normal-wound-healing-and-prevented-scar-formation-following-surgical-procedures-on-track-to-report-top-line-results-from-the-phase-3-trial-in-the-second-half-of-2024

PRF-110 promoted normal wound healing and prevented scar formation following surgical procedures Company reaffirms it is on tra...

 painreforms-new-manufacturing-process-achieves-18-month-stability-of-prf-110-at-room-temperature

PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical compan...

 on-june-24-painreform-ilan-hadar-ceo--cfo-ceased-his-service-to-co-appointed-ehud-geller-as-interim-ceo--cfo

- SEC Filing

 maxim-group-reiterates-buy-on-painreform-maintains-2-price-target

Maxim Group analyst Naz Rahman reiterates PainReform (NASDAQ:PRFX) with a Buy and maintains $2 price target.

 painreform-completes-enrollment-in-second-part-of-its-phase-3-bunionectomy-trial-for-prf-110

PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical compan...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION